查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1590817

泌尿生殖藥物市場：按產品、適應症、藥物類型 - 全球預測 2025-2030

Genitourinary Drugs Market by Product (Anti-infectives, Gynecological, Hormonal Therapy), Indication (Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer), Drug Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年泌尿生殖藥物市場價值為383億美元，預計2024年將達到398.3億美元，複合年成長率為4.17%，到2030年將達到510.1億美元。

泌尿生殖藥物市場主要涉及用於治療影響生殖和泌尿器官系統的疾病的藥物。這包括治療尿道感染、勃起功能障礙、尿失禁、膀胱過動症和其他相關病症的藥物。由於老化和生活方式改變等因素，泌尿器官系統疾病的盛行率日益增加，支持了對該市場的需求。這些療法的應用涵蓋各種醫療保健環境，包括醫院、診所和居家照護，目標最終使用者是需要急性和慢性治療解決方案的患者。關鍵的成長要素包括生物技術和藥物的進步，促進更有效和更有針對性的治療方法的開發，診斷工具的改進，加強早期檢測，以及醫療保健成本的上升。

主要市場統計
基準年[2023] 383億美元
預測年份 [2024] 398.3億美元
預測年份 [2030] 510.1億美元
複合年成長率（%） 4.17%

最近的市場機會來自擴大採用具有更高治療效率和更少副作用的個人化醫療和生技藥品。透過利用這些，公司可以專注於開發適合個別患者基因特徵的藥物。另一個有前景的領域是數位治療，它透過整合增強患者依從性和監測的技術來改善治療結果。阻礙市場擴張的挑戰包括嚴格的監管核准減緩新藥的推出、研發成本上升以及導致學名藥競爭的專利到期。隨著醫療保健系統努力控制成本，定價壓力和報銷問題進一步限制了市場。

創新的重點是探索新的藥物輸送系統，例如奈米顆粒和緩釋性，這些系統可以解決患者的依從性並提高藥物療效。此外，針對罕見泌尿系統疾病的未滿足需求可能會提供利基市場成長機會。在持續的研發努力的推動下，市場的本質是競爭激烈且快速發展。策略夥伴關係和研究合作可以提供一種整合資源並加速開發新藥的方法。總之，為了確保泌尿生殖藥物市場的持續成長和競爭優勢，保持對研發的明確關注、適應監管更新並應對技術進步非常重要。

市場動態：快速發展的泌尿生殖藥物市場的關鍵市場洞察

供需的動態交互作用正在改變泌尿生殖醫學市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 泌尿生殖系統疾病盛行率增加
    • 管道藥物增加
    • 人們越來越擔心尿失禁和陽痿
  • 市場限制因素
    • 市面上有仿冒品和學名藥
  • 市場機會
    • 製藥公司的聯合研發舉措
    • 擴大醫療保健投資以改善治療
  • 市場挑戰
    • 缺乏用藥依從性
    • 專利到期

波特的五力策略工具駕馭泌尿生殖藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解泌尿生殖藥物市場的外部影響

外部宏觀環境因素在塑造泌尿生殖藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解泌尿生殖醫學市場的競爭狀況

對泌尿生殖藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣泌尿生殖藥物市場供應商的績效評估

FPNV定位矩陣是評估泌尿生殖藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪泌尿生殖藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對泌尿生殖藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 泌尿生殖系統疾病盛行率增加
      • 管道藥物增加
      • 人們越來越關注尿失禁和陽痿
    • 抑制因素
      • 市面上有假藥和學名藥
    • 機會
      • 製藥公司的聯合研發舉措
      • 增加醫療保健投資以改善治療
    • 任務
      • 缺乏合規性
      • 專利持續到期
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章泌尿生殖藥物市場：依產品

  • 抗感染
  • 婦科
  • 荷爾蒙療法
  • 泌尿系統

第7章依適應症分列的泌尿生殖藥物市場

  • 良性攝護腺增生
  • 膀胱癌
  • 子宮頸癌
  • 勃起功能障礙
  • 血尿
  • 間質性膀胱炎
  • 卵巢癌
  • 攝護腺癌
  • 腎癌
  • 性行為感染傳染病
  • 尿失禁和膀胱過動症
  • 尿道感染

第8章按藥物類型分類的泌尿生殖藥物市場

  • 荷爾蒙療法
  • 陽痿藥物
  • 尿路解痙藥
  • 尿液pH調節劑
  • 子宮鬆弛劑
  • 子宮興奮劑

第9章：美洲泌尿生殖藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太泌尿生殖藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲/中東/非洲泌尿生殖醫學市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Asieris Pharmaceuticals
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cipla Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol Myers Squibb Company
Product Code: MRR-ED54C46E88A6

The Genitourinary Drugs Market was valued at USD 38.30 billion in 2023, expected to reach USD 39.83 billion in 2024, and is projected to grow at a CAGR of 4.17%, to USD 51.01 billion by 2030.

The genitourinary drugs market is primarily concerned with medications used to treat disorders affecting the genital and urinary systems. This encompasses drugs for urinary tract infections, erectile dysfunction, urinary incontinence, overactive bladder, and other related conditions. The necessity of this market is underscored by the rising prevalence of genitourinary disorders due to factors such as aging populations and lifestyle changes. The application of these drugs spans across various healthcare settings, including hospitals, clinics, and homecare, with targeted end-users being patients requiring both acute and chronic treatment solutions. Key growth influencers include advances in biotechnology and pharmaceuticals, which facilitate the development of more effective and targeted therapies, improved diagnostic tools enhancing early detection, and growing healthcare expenditure.

KEY MARKET STATISTICS
Base Year [2023] USD 38.30 billion
Estimated Year [2024] USD 39.83 billion
Forecast Year [2030] USD 51.01 billion
CAGR (%) 4.17%

Recent opportunities in the market emerge from the increasing adoption of personalized medicine and biologics, which possess high therapeutic efficiency and fewer side effects. Leveraging these, companies can focus on developing drugs tailored to individual patient genetic profiles. Another promising area lies in digital therapeutics, integrating technology for enhanced patient adherence and monitoring, thereby improving treatment outcomes. Challenges limiting market expansion include stringent regulatory approvals that delay the introduction of new drugs, high R&D costs, and patent expirations leading to generic competition. Pricing pressures and reimbursement issues further compound market constraints as healthcare systems strive to control costs.

Innovation can pivot towards exploring novel drug delivery systems such as nanoparticles and sustained-release formulations, catering to patient compliance and enhancing drug efficacy. Additionally, targeting unmet needs in rare urological disorders could yield niche market growth opportunities. The market's nature is distinctly competitive and fast-evolving, driven by continuous research and development efforts. Strategic partnerships and collaborations could offer ways to consolidate resources and hasten new drug development. In conclusion, maintaining a clear focus on R&D, adaptation to regulatory updates, and responsiveness to technological advances are critical for sustained growth and competitive advantage in the genitourinary drugs market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genitourinary Drugs Market

The Genitourinary Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of genitourinary disorders
    • Rising number of pipeline drugs
    • Growing concerns about urinary incontinence and impotence
  • Market Restraints
    • Availability of counterfeit and generics drugs in the market
  • Market Opportunities
    • Collaborative R&D efforts by the pharma companies
    • Growing investment in healthcare for improved treatments
  • Market Challenges
    • Lack of compliance to medication
    • Continual patent expirations

Porter's Five Forces: A Strategic Tool for Navigating the Genitourinary Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genitourinary Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genitourinary Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genitourinary Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genitourinary Drugs Market

A detailed market share analysis in the Genitourinary Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genitourinary Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genitourinary Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genitourinary Drugs Market

A strategic analysis of the Genitourinary Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genitourinary Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Asieris Pharmaceuticals, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cipla Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., and The Bristol Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Genitourinary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Anti-infectives, Gynecological, Hormonal Therapy, and Urologicals.
  • Based on Indication, market is studied across Benign Prostatic Hyperplasia, Bladder Cancer, Cervical Cancer, Erectile Dysfunction, Hematuria, Interstitial Cystitis, Ovarian Cancer, Prostate Cancer, Renal Cancer, Sexually Transmitted Diseases, Urinary Incontinence & Overactive Bladder, and Urinary Tract Infections.
  • Based on Drug Type, market is studied across Hormonal Therapy, Impotence Agents, Urinary Antispasmodics, Urinary pH Modifiers, Uterine Relaxants, and Uterine Stimulants.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genitourinary disorders
      • 5.1.1.2. Rising number of pipeline drugs
      • 5.1.1.3. Growing concerns about urinary incontinence and impotence
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of counterfeit and generics drugs in the market
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative R&D efforts by the pharma companies
      • 5.1.3.2. Growing investment in healthcare for improved treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of compliance to medication
      • 5.1.4.2. Continual patent expirations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genitourinary Drugs Market, by Product

  • 6.1. Introduction
  • 6.2. Anti-infectives
  • 6.3. Gynecological
  • 6.4. Hormonal Therapy
  • 6.5. Urologicals

7. Genitourinary Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Benign Prostatic Hyperplasia
  • 7.3. Bladder Cancer
  • 7.4. Cervical Cancer
  • 7.5. Erectile Dysfunction
  • 7.6. Hematuria
  • 7.7. Interstitial Cystitis
  • 7.8. Ovarian Cancer
  • 7.9. Prostate Cancer
  • 7.10. Renal Cancer
  • 7.11. Sexually Transmitted Diseases
  • 7.12. Urinary Incontinence & Overactive Bladder
  • 7.13. Urinary Tract Infections

8. Genitourinary Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Hormonal Therapy
  • 8.3. Impotence Agents
  • 8.4. Urinary Antispasmodics
  • 8.5. Urinary pH Modifiers
  • 8.6. Uterine Relaxants
  • 8.7. Uterine Stimulants

9. Americas Genitourinary Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Genitourinary Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Genitourinary Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Asieris Pharmaceuticals
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Bayer AG
  • 7. Cipla Inc.
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. GlaxoSmithKline PLC
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer, Inc.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. The Bristol Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. GENITOURINARY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GENITOURINARY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENITOURINARY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENITOURINARY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HEMATURIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SEXUALLY TRANSMITTED DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY INCONTINENCE & OVERACTIVE BLADDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IMPOTENCE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY ANTISPASMODICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY PH MODIFIERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UTERINE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UTERINE STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SOUTH KOREA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. TAIWAN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. THAILAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. VIETNAM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. DENMARK GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EGYPT GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. FINLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. FRANCE GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. GERMANY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. ISRAEL GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ITALY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. ITALY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. ITALY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. NETHERLANDS GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. NIGERIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. NORWAY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. POLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. POLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. POLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. QATAR GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. QATAR GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. QATAR GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. RUSSIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SAUDI ARABIA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. SPAIN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. SWEDEN GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. SWITZERLAND GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. TURKEY GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED ARAB EMIRATES GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. UNITED KINGDOM GENITOURINARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 160. GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023